Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 6, 2004, Pages 595-602

  Bucci, Mary K ^a,b   Rosenthal, David I ^a,c   Hershock, Diane ^a   Metz, James ^a   Devine, Pamela ^a   Kligerman, Morton M ^a   Machtay, Mitchell ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Accelerated radiotherapy; Chemoradiation; Paclitaxel; Squamous cell carcinoma of the head and neck

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESOPHAGUS STRICTURE; FEMALE; FOLLOW UP; GASTROSTOMY; HEAD AND NECK CANCER; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NASOPHARYNX CANCER; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; TRACHEOSTOMY;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 10044265306     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000135738.85334.ed     Document Type: Article

References (43)

1. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 90-03. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
2. Calais G, Alfonsi M, Bardet E, et al. Randomized study comparing radiation alone RT versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
3. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol. 2003;1:92-98.
4. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949-955.
5. Brizel DM, Albers MA, Fisher SR, et al. A phase III trial of hyperfrac-tionated irradiation +/- concurrent chemotherapy for locally advanced carcinoma of the head and neck: superiority of combined treatment. Am Soc Clin Oncol. Denver, 1997; vol. 16.
6. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27: 131-146.
7. Spanos WJJ, Shukovsky LJ, Fletcher GH. Time, dose, and tumor volume relationships in irradiation of squamous cell carcinomas of the base of the tongue. Cancer. 1976;37:2591-2599.
8. Hansen O, Overgaard J, Hansen HS, Overgaard M, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol. 1997;43:47-51.
9. Awwad HK, Lotayef M, Shouman T, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the post-operative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer. 2002;86:517-523.
10. Poulsen MG, Denham JW, Peters LJ, et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol. 2001;60:113-122.
11. Haselow RE, Warshaw MG, Okin MM, et al. Radiation alone versus radiation plus weekly low dose cisplatin in unresectable cancer of the head and neck. In: Free WE, Johns ME, eds. Head and Neck Cancer. Vol. 1. Toronto: Marcel Dekker; 1990:279-281.
12. Forastiere A, Berkey B, Maor M, et al. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11 (abstr). Proc Am Soc Clin Oncol. (ASCO), San Francisco, 2001; Vol. 20.
13. Gabriele R, Orecchia R, Ragona, et al. A cooperative AIRO/Piemonte randomized clinical trial of carboplatin as an adjunct to radiotherapy in head and neck cancer. Radiother Oncol. 1994;32:S93.
14. Browman GP, Cripps D, Hodson, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994;12:2648-2653.
15. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitomycin randomized trials. J Clin Oncol. 1997;15:268-276.
16. Gupta NK, Pointon RCS, Wilkonson PM. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Cancer Radiol. 1987;38:575-581.
17. Hoffman W, Belka C, Schmidberger H, et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer - results from a phase I trial. Int J Radiat Oncol Biol Phys. 1997;38:691-696.
18. Rosenthal DI, Lee JH, Sinard R, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001;19:1363-1373.
19. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. Cancer. 1998;82:2270-2274.
20. Leonard C, Chan DC, Chou TC, et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 1996;56:5198-5204.
21. Elomaa L, Joensuu H, Kulmala J, et al. Squamous cell carcinoma is highly sensitive to Taxol: a possible new radiation sensitizer. Acta Otolaryngol. 1995;115:340-344.
22. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 1994;86: 441-446.
23. Zanelli GD, Quaia M, Robieux I, et al. Paclitaxel as a radiosensitizer: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 1997;33:486-492.
24. Gupta N, Hu LJ, Deen DF, et al. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys. 1997;37:885-895.
25. Rathmann J, Leopold KA, Rigas JR. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 1999;9:130-135.
26. Suntharalingam M, Haas ML, VanEcho DA, et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer. 2001;91:548-554.
27. Machtay M, Aviles V, Kligerman MM, et al. A phase I trial of 96-hour taxol infusion plus accelerated radiotherapy for unresectable head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:311-315.
28. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [editorial]. Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Garden AS, Pajak T, Vokes E, et al. Preliminary results of RTOG 9703 - a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck [abstr.]. Proc Am Soc Clin Oncol. (ASCO), San Francisco, 2001; Vol. 20.
31. Machtay M, Rosenthal DI, Algazy KM, et al. Pilot study of organ preservation multimodality therapy for locally advanced resectable oropharyngeal carcinoma. Am J Clin Oncol. 2000;23:509-515.
32. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania phase II trial. J Clin Oncol 2002;20:3964-3971.
33. VA Laryngeal Cancer Study Group, Wolf GT, Hong WK, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
34. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161-1171.
35. Ang KK, Harris J, Garden A, et al. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: preliminary results of a phase II trial of the RTOG (99-14) (abstr. #118). Proc Am Soc Ther Radiol Oncol (ASTRO), New Orleans, 2002. Int J Radiat Oncol Biol. 54(suppl 2):71.
36. Gray J, Meluch A, Greco F, et al. Induction paclitaxel/carboplatin/5FU followed by concurrent radiotherapy and weekly paclitaxel/carboplatin for patients with locally advanced head and neck cancer: a Minnie Pearl Cancer Research Network Trial (abstr. 900), Proc. Am. Soc. Clin. Oncol. (ASCO), 2001; Vol. 20.
37. Conley G, Jacobs M, Suntharalingam M, et al. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol. 1997;24:78-80.
38. Hershock DI, Santiago R, Smith R, et al. Weekly carboplatin and paclitaxel concurrent with radiation therapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC): preliminary results from the Hospital of the University of Pennsylvania experience (abstr. #969). Proc Am Soc Clin Oncol. (ASCO), Orlando, 2002; Vol. 21.
39. Glisson BS, Garden AS, Kies MS, et al. Phase I study of docetaxel (D), cisplatin (P), and concomitant boost radiation for patients with locally advanced squamous cancer of the head and neck (SCHN). Neck [Meeting abstract]. Proc Annu Meet Am Soc Clin Oncol (ASCO), Orlando, 2002;Vol. 21.
40. Glantz MJ, Choy H, Akerly W, et al. Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol. 1996;23:123-125.
41. Weng EY, Kane M, Simon G, et al. Concomitant boost radiation therapy (RT) with low-dose weekly carboplatin and Taxol for locally advanced squamous cell carcinoma of the head and neck: a feasibility and response study [abstr.]. Proc Am Soc Clin Oncol. 2001; Vol. 20.
42. Glisson B, Garden A, Kies M, et al. Phase II study of docetaxel (D), cisplatin (P), and concomitant boost radiation (CB-RT) for patients with locally advanced squamous cell cancer of the head and neck [abstr. #2011]. Proc Am Soc Clin Oncol. (ASCO), Chicago, 2003; Vol. 22.
43. Pfister DG, Aliff TB, Kraus DH, et al. Concurrent cetuximab, cisplatin and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): preliminary results of a new combined-modality paradigm [abstr. #1993]. Proc Am Soc Clin Oncol. (ASCO), Chicago, 2003; Vol. 22.